Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company logo
$767.76 +10.22 (+1.35%)
(As of 12/20/2024 05:45 PM ET)

About Eli Lilly and Company Stock (NYSE:LLY)

Key Stats

Today's Range
$766.61
$811.35
50-Day Range
$727.57
$931.16
52-Week Range
$567.02
$972.53
Volume
9.50 million shs
Average Volume
3.24 million shs
Market Capitalization
$728.85 billion
P/E Ratio
83.00
Dividend Yield
0.78%
Price Target
$1,002.22
Consensus Rating
Moderate Buy

Company Overview

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Eli Lilly and Company Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
100th Percentile Overall Score

LLY MarketRank™: 

Eli Lilly and Company scored higher than 100% of companies evaluated by MarketBeat, and ranked 3rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 17 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eli Lilly and Company has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eli Lilly and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Eli Lilly and Company are expected to grow by 79.29% in the coming year, from $13.18 to $23.63 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eli Lilly and Company is 83.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.45.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eli Lilly and Company is 83.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.58.

  • Price to Earnings Growth Ratio

    Eli Lilly and Company has a PEG Ratio of 3.02. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Eli Lilly and Company has a P/B Ratio of 67.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.69% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 10.70%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eli Lilly and Company has a dividend yield of 0.67%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Eli Lilly and Company does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Eli Lilly and Company is 64.86%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 25.39% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

  • Read more about Eli Lilly and Company's dividend.
  • Percentage of Shares Shorted

    0.69% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 10.70%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Eli Lilly and Company has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 59 news articles for Eli Lilly and Company this week, compared to 49 articles on an average week.
  • Search Interest

    Only 141 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    81 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 7% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $723,042.00 in company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

  • Percentage Held by Institutions

    82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eli Lilly and Company's insider trading history.
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Novo Nordisk weight loss injection
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon (LLY)
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.
Stuttgart, Germany - 07-08-2024: Mobile phone with webpage of US online education company Stride Inc. in front of business logo. Focus on top-left of phone display. — Stock Editorial Photography
4 Stocks That Crushed Analyst Estimates by More Than Double (LLY)
Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Vials of liquid on a white table and the logo Amgen, large pharmaceutical company. March 15, 2021. Barnaul, Russia.
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair? (LLY)
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
David Ricks, chair and CEO of Eli Lilly, fields a question during an announcement of the company's …
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products
See More Headlines

LLY Stock Analysis - Frequently Asked Questions

Eli Lilly and Company's stock was trading at $582.92 at the beginning of 2024. Since then, LLY shares have increased by 31.7% and is now trading at $767.76.
View the best growth stocks for 2024 here
.

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings data on Wednesday, October, 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by $0.34. Eli Lilly and Company's revenue was up 20.4% on a year-over-year basis.
Read the conference call transcript
.

Eli Lilly and Company's Board of Directors initiated a share buyback plan on Monday, December 9th 2024, which permits the company to repurchase $15,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.

Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others.

Top institutional investors of Eli Lilly and Company include PNC Financial Services Group Inc. (5.41%), State Street Corp (3.57%), FMR LLC (3.48%) and Primecap Management Co. CA (1.86%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

Last Earnings
10/30/2024
Ex-Dividend for 12/10 Dividend
11/15/2024
Dividend Payable
12/10/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$1,002.22
High Stock Price Target
$1,250.00
Low Stock Price Target
$723.00
Potential Upside/Downside
+30.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
21 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
24.84%

Debt

Sales & Book Value

Annual Sales
$40.86 billion
Cash Flow
$7.36 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
948,082,000
Market Cap
$728.85 billion
Optionable
Optionable
Beta
0.41

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSE:LLY) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners